News | September 21, 2009

GE Highlights Innovations in Molecular Imaging at WMIC

Discovery PET/CT 690

September 21, 2009 - GE Healthcare hosts two consortium workshops on imaging technologies and molecular imaging agents at the World Molecular Imaging Congress (WMIC) September 23-26, 2009, in Montreal, Canada.

At the GE Healthcare WMIC booth #302, the company will introduce new diagnostic imaging applications, GE Healthcare’s pre-clinical imaging serves the development of new therapeutics and tracers by using newest imaging technologies with animal disease models. The eXplore speCZT, the first full-ring solid-state detector small animal SPECT, focuses on high throughput and rapid dynamic imaging. The system utilizes a cadmium zinc telluride (CZT) detector with high-energy resolution to enable dual or triple radionuclide imaging. The system also has the capability to combine with the world-class CT120 X-ray CT system for seamless dual-modality imaging, and fusion. In this configuration, users can benefit from improved quantitative accuracy in measuring SPECT tracer uptake with our new SPECT/CT Attenuation Correction feature.

Understanding researcher’s multi-modality needs, the Triumph pre-clinical system, is an all digital, fully integrated molecular imaging system for biomedical research and pharmaceutical development, designed to accommodate any combination of SPECT, PET and CT.

Molecular imaging is only possible with the latest in imaging agents and radiopharmaceuticals. TRACERlab FX synthesizers are designed for the production these PET tracers. Worldwide researchers use TRACERlabs for the synthesis of common tracers and the rapid development of new PET imaging agents. GE Healthcare aims to simplify the complexity of radiopharmacy infrastructure into a single touch-point solution. TRACERcenter-GMP is a combination of equipment, information and services that allow you to establish and operate your research or clinical PET tracer production center with confidence by providing state-of-the-art instrumentation, comprehensive documentation and GMP training and consulting services to provide new centers with support and knowledge for the production of PET tracers.

The Discovery PET/CT 600 series continues to expand with the introduction of the Discovery PET/CT 690 – a molecular imaging tool designed go beyond the needs of the clinical practice and provide the necessary tools and technologies to explore the future of PET/CT imaging. With specialized detector configuration designed for sensitivity, event throughput and efficiency, researchers and clinicians have the necessary speed in workflow, protocol flexibility and unique timing resolution technology to help forge new frontiers in clinical techniques, drug discovery and motion management.

The IN Cell Analyzer 2000 is a flexible cell imaging system for High Content Analysis with excellent image quality, speed and ease-of-use for all screening and research needs. The flexibility of the system enables scientists to perform a wide variety of previously challenging experiments with a single instrument: from investigative microscopy through to automated screening, and imaging of organelles, cells, tissues and whole organisms.

In addition, GE will host workshops at WMIC. These are the following:

Innovations in Pre-Clinical Molecular Imaging (Thursday, September 24th, 5:40pm – 7:10pm): Track the molecular progression of disease and response to therapeutics over time in small animals to accelerate research. This session will explore core emerging technologies and applications through GE Healthcare's small animal molecular imaging systems in the journey to understand disease, from the beginning.

Current Topics in PET Tracer Research (Friday, September 25th, 7:30am – 9:00am) To nderstanddisease, from the beginning, molecular imaging requires the convergence of imaging agents and equipment. In this session, researchers from the academic community and from GE Healthcare will present and discuss progress in development and validation of new PET tracers.

For more information:

Related Content

Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Siemens Healthineers Showcases syngo Virtual Cockpit for More Flexible Workforce Management
News | Teleradiology | November 25, 2018
During the 104th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Nov. 25-30...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc.
Bruker Introduces New High-Performance Preclinical PET/CT Si78 System
Technology | PET-CT | September 26, 2018
September 26, 2018 — Bruker recently announced the introduction of the new preclinical...
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...
Abnormal Protein Concentrations Found in Brains of Military Personnel With Suspected CTE

Researchers are using the tracer, which is injected into a patient, then seen with a PET scan, to see if it is possible to diagnose chronic traumatic encephalopathy in living patients. In this image, warmer colors indicate a higher concentration of the tracer, which binds to abnormal proteins in the brain. Credit UCLA Health.

News | PET Imaging | August 24, 2018
August 24, 2018 — In a small study of
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...